BioNTech (BNTX) Competitors

BioNTech (NASDAQ:BNTX) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, community ranking, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

Does the MarketBeat Community favor BNTX or GSK?

GSK received 679 more outperform votes than BioNTech when rated by MarketBeat users. Likewise, 57.04% of users gave GSK an outperform vote while only 45.87% of users gave BioNTech an outperform vote.

Company	Underperform	Outperform
BioNTech	Outperform Votes 139 45.87%	Underperform Votes 164 54.13%
GSK	Outperform Votes 818 57.04%	Underperform Votes 616 42.96%

Which has more volatility and risk, BNTX or GSK?

BioNTech has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500.

Is BNTX or GSK more profitable?

GSK has a net margin of 7.97% compared to BioNTech's net margin of -15.16%. GSK's return on equity of 50.62% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-15.16%	-2.35%	-2.05%
GSK	7.97%	50.62%	11.54%

Do analysts rate BNTX or GSK?

BioNTech currently has a consensus price target of $140.76, suggesting a potential upside of 23.53%. GSK has a consensus price target of $43.25, suggesting a potential upside of 26.91%. Given GSK's higher probable upside, analysts plainly believe GSK is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	0 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.82
GSK	0 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	3 Strong Buy rating(s)	2.60

Which has higher earnings and valuation, BNTX or GSK?

GSK has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.04B	8.99	$1.01B	-$2.10	-54.26
GSK	$31.31B	2.26	$6.13B	$1.54	22.13

Do institutionals and insiders believe in BNTX or GSK?

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Comparatively, 10.0% of GSK shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Does the media refer more to BNTX or GSK?

In the previous week, BioNTech had 7 more articles in the media than GSK. MarketBeat recorded 12 mentions for BioNTech and 5 mentions for GSK. BioNTech's average media sentiment score of 0.37 beat GSK's score of 0.23 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	0 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
GSK	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Is BNTX or GSK a better dividend stock?

BioNTech pays an annual dividend of $1.53 per share and has a dividend yield of 1.3%. GSK pays an annual dividend of $1.52 per share and has a dividend yield of 4.5%. BioNTech pays out -72.9% of its earnings in the form of a dividend. GSK pays out 98.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Summary

GSK beats BioNTech on 14 of the 21 factors compared between the two stocks.